What question did this study set out to answer?

This letter aims to address findings regarding dapagliflozin's efficacy in patients with heart failure.

June 2, 2026

Letter by Qin et al Regarding Article “Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure”

Key Points

This letter aims to address findings regarding dapagliflozin's efficacy in patients with heart failure.
Analysis of primary results from the DAPA ACT HF-TIMI 68 trial.
Discussion of meta-analysis outcomes of sodium-glucose cotransporter-2 inhibitors.
Focus on results in hospitalized heart failure patients.
Dapagliflozin showed significant benefits for heart failure management.
Meta-analysis indicated positive outcomes for sodium-glucose cotransporter-2 inhibitors.
Clinical outcomes emphasized the importance of these findings for treatment strategies.

Expert Takes3 quotes

1/3

“The totality of randomized trial data really suggests that starting SGLT2 inhibitors during heart failure hospitalization reduces the early risk of cardiovascular death or worsening heart failure and all-cause mortality in the early postdischarge period.”

David Berg, Investigator, TIMI Study Group, Brigham and Women's HospitalBrigham and Women's Hospitalauto_pipelineView source

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper